Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.61 |
| ▸ | BRD2 | P25440 | 2/20 | 0.46 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16696830 | 0.91 | BRD4 (0.51) | BRD4BRD2GRIN2B | |
| SCHEMBL16696546 | 0.89 | BRD4 (0.61) | BRD4BRD2BRD3PTGDR2 | |
| SCHEMBL16697140 | 0.86 | BRD4 (0.69) | BRD4BRD2BRD3 | |
| SCHEMBL16697074 | 0.86 | BRD4 (0.65) | BRD4BRD2 | |
| SCHEMBL16696893 | 0.85 | BRD4 (0.60) | BRD4BRD2GRIN2B | |
| SCHEMBL16697527 | 0.84 | BRD4 (0.61) | BRD4BRD2 | |
| SCHEMBL16697571 | 0.84 | BRD4 (0.57) | BRD4BRD2PTGDR2 | |
| SCHEMBL16696809 | 0.82 | BRD4 (0.52) | BRD4 | |
| SCHEMBL16697885 | 0.82 | BRD4 (0.59) | BRD4BRD2PTGDR2 | |
| SCHEMBL16697058 | 0.82 | BRD4 (0.60) | BRD4BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-9718847-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718847-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718847-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP2C19 | BRD4 1365/4885BRD2 2805/4885BRD3 2759/4885 |
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP2C19 | BRD4 1365/4885BRD2 2805/4885BRD3 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.